Table 3. Genotypes of VDR polymorphisms and NSCLC patients survival.
| Genotype | Cases | Deaths | MST (Months) | Crude HR (95% CIs) | Adjusted HR (95% CIs)* |
|---|---|---|---|---|---|
| rs739837 | n=568 | n=311 | |||
| CC | 309 | 164 | 26.2 | 1.00 | 1.00 |
| AC | 219 | 120 | 23.5 | 1.07 (0.85-1.36) | 1.26 (0.99-1.61) |
| AA | 40 | 27 | 21.4 | 1.52 (1.01-2.29) | 2.00 (1.32-3.04) |
| AA vs AC/CC | 40/528 | 27/284 | 21.4/25.1 | 1.48 (1.00-2.20) | 1.82 (1.21-2.72) |
| rs731236 | n = 560 | n =307 | |||
| AA | 496 | 265 | 26.2 | 1.00 | 1.00 |
| AG | 60 | 39 | 19.1 | 1.44 (1.03-2.02) | 1.41 (1.00-1.99) |
| GG | 4 | 3 | 11.4 | 2.63 (0.84-8.28) | 4.26 (1.32-13.8) |
| AG/GG vs AA | 64/496 | 42/265 | 18.4/26.2 | 1.49 (1.07-2.07) | 1.49 (1.07-2.08) |
| rs1544410 | n = 562 | n = 307 | |||
| GG | 505 | 268 | 26.4 | 1.00 | 1.00 |
| AG | 53 | 36 | 18.2 | 1.59 (1.12-2.26) | 1.55(1.09-2.21) |
| AA | 4 | 3 | 11.4 | 2.66 (0.85-8.25) | 4.33(1.34-14.0) |
| AG/AA vs GG | 57/505 | 39/268 | 18.2/26.4 | 1.64 (1.17-2.31) | 1.64(1.16-2.31) |
*Adjusted for age, gender, smoking status, stage, histology, surgical operation and chemotherapy or radiation treatment.